AEON Biopharma (AEON) just unveiled an announcement.
AEON Biopharma, Inc. revealed preliminary findings from a Phase 2 trial of ABP-450, a potential chronic migraine preventive treatment, on May 3, 2024. The study didn’t meet its primary goal, as the medication’s effectiveness was not statistically significant when compared to a placebo. Despite the expected decrease in monthly migraine days for the treatment arms, the placebo arm showed an unexpectedly high decrease, blurring the treatment’s perceived benefits. These results suggest more research is needed to assess ABP-450’s true efficacy.
Learn more about AEON stock on TipRanks’ Stock Analysis page.
